Published in Inflamm Bowel Dis on August 01, 2008
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis (2014) 2.17
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.81
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut (2011) 1.52
Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis (2007) 1.46
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. J Gastrointest Surg (2013) 1.42
Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci (2002) 1.28
MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology (2005) 1.23
Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol (2008) 1.13
Risk of postoperative recurrence and postoperative management of Crohn's disease. World J Gastroenterol (2011) 1.12
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis (2013) 1.12
Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis (2005) 1.03
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence. Clin Chem Lab Med (2004) 1.02
Biological therapy for ulcerative colitis: what is after anti-TNF. Curr Drug Targets (2011) 0.97
Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion (2008) 0.93
Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? Dig Dis (2012) 0.93
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol (2011) 0.92
Familial aggregation in inflammatory bowel disease: is it genes or environment? World J Gastroenterol (2011) 0.92
Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance. Curr Med Chem (2007) 0.90
Catching the therapeutic window of opportunity in early Crohn's disease. Curr Drug Targets (2014) 0.89
99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging (2003) 0.89
Hydrogen breath test for diagnosis of lactose malabsorption: the importance of timing and the number of breath samples. Can J Gastroenterol (2006) 0.89
Mucosal healing in ulcerative colitis: where do we stand? Curr Drug Targets (2011) 0.89
Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis (2011) 0.89
Internet use among inflammatory bowel disease patients: an Italian multicenter survey. Eur J Gastroenterol Hepatol (2009) 0.88
Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets (2013) 0.85
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol (2013) 0.85
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. World J Gastroenterol (2010) 0.84
Monthly and seasonal birth patterns and the occurrence of Crohn's disease. Am J Gastroenterol (2009) 0.84
Self-reported milk intolerance in irritable bowel syndrome: what should we believe? Clin Nutr (2004) 0.84
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. J Gastrointest Surg (2012) 0.84
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. Scand J Gastroenterol (2013) 0.84
Ferritin as a simple indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis (2006) 0.83
Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis (2009) 0.82
Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm Bowel Dis (2008) 0.82
GI distension in severe ulcerative colitis. Am J Gastroenterol (2002) 0.81
In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohns Colitis (2010) 0.81
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. J Clin Invest (2016) 0.80
Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev (2008) 0.80
Natalizumab in the treatment of Crohn's disease. Biologics (2008) 0.80
Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. Curr Drug Targets (2013) 0.80
Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol (2013) 0.80
IL-1beta-511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: An Italian population study and meta-analysis of European studies. Dig Liver Dis (2009) 0.79
Medical therapy for Crohn's disease: top-down or step-up? Dig Dis (2007) 0.79
Smad3 knock-out mice as a useful model to study intestinal fibrogenesis. World J Gastroenterol (2006) 0.79
The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man. Dig Dis (2015) 0.79
Inflammatory bowel diseases: clinical update of practical guidelines. Nucl Med Commun (2005) 0.78
The long journey of salicylates in ulcerative colitis: The past and the future. J Crohns Colitis (2009) 0.78
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update. Expert Rev Clin Immunol (2013) 0.78
Hydrogen breath test for the diagnosis of lactose intolerance, is the routine sugar load the best one? World J Gastroenterol (2008) 0.78
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. Scand J Gastroenterol (2015) 0.78
Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review. J Crohns Colitis (2011) 0.77
Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: an IG-IBD study. J Crohns Colitis (2010) 0.77
Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Dig Liver Dis (2013) 0.77
Mesenteric adenitis caused by Yersinia pseudotubercolosis in a patient subsequently diagnosed with Crohn's disease of the terminal ileum. World J Gastroenterol (2006) 0.77
Regulatory T-cell therapy for Crohn's disease: in vivo veritas. Gastroenterology (2012) 0.77
Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol (2011) 0.77
Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int J Colorectal Dis (2006) 0.77
Frequency and Cause of Persistent Symptoms in Celiac Disease Patients on a Long-term Gluten-free Diet. J Clin Gastroenterol (2016) 0.77
Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. Inflamm Bowel Dis (2007) 0.76
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? Gut (2013) 0.76
Development of fistulae in ileo-anal pouch does not necessarily indicate Crohn's disease. Am J Gastroenterol (2004) 0.75
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2016) 0.75
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol (2014) 0.75
Clinical course of late-onset Crohn's disease. Inflamm Bowel Dis (2009) 0.75
Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. Inflamm Bowel Dis (2007) 0.75
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion (2017) 0.75
Cross-sectional imaging modalities in Crohn's disease. Dig Dis (2013) 0.75
The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. Curr Drug Targets (2012) 0.75
Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies. Inflamm Bowel Dis (2009) 0.75
Iron deficiency: the hidden miscreant in inflammatory bowel disease. Curr Drug Targets (2014) 0.75
Acute severe colitis: infliximab and/or cyclosporine? Curr Drug Targets (2011) 0.75
Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy (2015) 0.75
Perianal fistulas mimicking Crohn's disease in HIV-infected male patient. Am J Gastroenterol (2009) 0.75
Ulcerative colitis and granulocyte-monocyte-apheresis: safety and efficacy of maintenance therapy during pregnancy. J Clin Apher (2014) 0.75
Oral beclomethasone: a review of its use in inflammatory bowel disease. Mini Rev Med Chem (2008) 0.75
Adalimumab for the treatment of pediatric Crohn's disease. Expert Rev Clin Immunol (2015) 0.75
State of the art: psychotherapeutic interventions targeting the psychological factors involved in IBD. Curr Drug Targets (2014) 0.75
Capsule endoscopy in Crohn's disease. Curr Drug Targets (2012) 0.75
European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. Eur J Gastroenterol Hepatol (2016) 0.75